All Type of News
Handok-Genexine co-develop growth hormone, selected as orphan drug from FDA
‘GX-H9,’ a long-acting growth hormone that is being co-developed by Handok(Chairman Young-Jin Kim) and Genexine(CEO Han-Soo Kyung), was selected as an orphan drug to treat growth hormone deficiency from the U.S. Food ...
BMS, “Targeted combination therapies are the best for cancer patients”
BMS Pharmaceutical recommended combined targeted therapies as the best treatment for cancer patients, and announced a plan to continue and extend researches related to this.
On the 16th, BMS Pharmaceutical Korea rev...
SK Chemicals’ hemophilia therapy ‘AFSTYLA’ on the way to enter EUOn the 15th, SK Chemicals(President Man-Hoon Park) announced the hemophilia treatment ‘AFSTYLA’ was recommended by the Committee for Medicinal Products for Human Use(CHMP), an a...
|
.jpg)
KPDA carries out both accusation on AhyeonCare and revision to Pharmaceutical Affairs Law
With accusation of expedient direct wholesaling, the Korea Pharmaceutical Distribution Association(KPDA) will push forwards with an amendment to the Pharmaceutical Affairs Law.
On the 16th, the KPDA held the 3rd boar...
Listed pharmas reduces R&D investments to overcome weakened profitability
Since some pharmaceutical companies’ profitability has been weakened, their short-sighted business management, which decreases investments in R&D, has been criticized.
According to the analysis result of the KOSPI an...
Hepatitis B therapy ‘Virea’ sold for more than KRW 100 billion in 9 months
The collective sales of the Yuhan Corporation’s hepatitis B treatment ‘Viread’ by the last September were aggregated to exceed KRW 100 billion.
According to Yuhan Corporation, its 2016 third quarter’s collective sale...
Pharma industry paying sharp attention to prosecution’s addition investigation
Pharmaceutical companies have paid sharp attention to the result of the Novartis’ rebate case.
According to the pharmaceutical industry, while the trial for Novartis and some of the press is scheduled to be held on t...
Hanmi Pharm diversifies volumes and dosage forms of Korean influenza drug ‘Hanmi Fly’So far, Hanmi Pharm has localized influenza treatments in Korea which had depended on foreign ones, and diversified their volumes and dosage forms.
On the 14th, Hanmi Pharm(CEO...
|
Large dist. companies use return-by-the-piece policy to compete over clients
Large pharmaceutical distribution companies have competed each other over return by the piece.
While Baekje Pharmaceutical started to enlarge the number of clients based on newly signing agreements of return by the p...
MFDS becomes member of ‘ICH,’ international council for drug regulation
On the 14th, the Ministry of Food and Drug Safety(MFDS) announced Korea become a member at the ‘2016 2nd Half’s General Meeting for International Council on Harmonisation(ICH)’ held in Osaka, Japan.
The membership i...
